特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Actinium Pharmaceuticals, Inc.の製品パイプライン分析

Actinium Pharmaceuticals, Inc. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 256032
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.57円で換算しております。
Actinium Pharmaceuticals, Inc.の製品パイプライン分析 Actinium Pharmaceuticals, Inc. - Product Pipeline Review - 2016
出版日: 2016年08月24日 ページ情報: 英文 45 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

Actinium Pharmaceuticals, Inc.は米国に本社を置くバイオ製薬企業で、アルファ線放出抗体を中心としたがん治療薬の開発に注力しています。

当レポートでは、Actinium Pharmaceuticals, Inc. における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Actinium Pharmaceuticals, Inc. の基本情報

  • Actinium Pharmaceuticals, Inc. の概要
  • 主要情報
  • 企業情報

Actinium Pharmaceuticals, Inc. :R&Dの概要

  • 主な治療範囲

Actinium Pharmaceuticals, Inc. :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Actinium Pharmaceuticals, Inc. :パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 第3相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

Actinium Pharmaceuticals, Inc. :薬剤プロファイル

  • Iomab-B
  • HuM195-Ac-225
  • AAA-225
  • Actimab-B
  • Actimab-Br
  • Actimab-C
  • Actimab-P
  • Monoclonal Antibody Conjugate for Cancer

Actinium Pharmaceuticals, Inc. :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Actinium Pharmaceuticals, Inc. :最近のパイプライン情報

Actinium Pharmaceuticals, Inc. :開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品

Actinium Pharmaceuticals, Inc. :本社と子会社の所在地

  • 本社
  • その他支社および子会社

付録

図表一覧

目次
Product Code: GMDHC08122CDB

Summary:

Global Markets Direct's, 'Actinium Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the Actinium Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Actinium Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of Actinium Pharmaceuticals, Inc.
  • The report provides overview of Actinium Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Actinium Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Actinium Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate Actinium Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Actinium Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Actinium Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Actinium Pharmaceuticals, Inc. Snapshot
    • Actinium Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Actinium Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Actinium Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Actinium Pharmaceuticals, Inc. - Pipeline Products Glance
    • Actinium Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Actinium Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Actinium Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Actinium Pharmaceuticals, Inc. - Drug Profiles
    • Iomab-B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Actimab-A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-8Y90
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-8SA
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Actimab-B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Actimab-Br
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Actimab-C
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Actimab-P
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate for Hematological Tumor and Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Actinium Pharmaceuticals, Inc. - Pipeline Analysis
    • Actinium Pharmaceuticals, Inc. - Pipeline Products by Target
    • Actinium Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Actinium Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Actinium Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Actinium Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Actinium Pharmaceuticals, Inc. - Dormant Projects
  • Actinium Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • Bismab-A
  • Actinium Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Actinium Pharmaceuticals, Inc., Key Information
  • Actinium Pharmaceuticals, Inc., Key Facts
  • Actinium Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Actinium Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Actinium Pharmaceuticals, Inc. - Phase III, 2016
  • Actinium Pharmaceuticals, Inc. - Phase II, 2016
  • Actinium Pharmaceuticals, Inc. - Phase I, 2016
  • Actinium Pharmaceuticals, Inc. - Preclinical, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Actinium Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
  • Actinium Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
  • Actinium Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016

List of Figures

  • Actinium Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Actinium Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016